The hypoxic tumour microenvironment and metastatic progression

Clinical and Experimental Metastasis

Volumn 20, Issue 3, 2003, Pages 237-250

  Subarsky, Patrick ^a   Hill, Richard P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Angiogenesis; Gene expression; Hypoxia; Metastasis; Tumour microenvironment

Indexed keywords

ANGIOPOIETIN; BASIC FIBROBLAST GROWTH FACTOR; CARBONATE DEHYDRATASE; COLLAGEN TYPE 5; COLLAGENASE 3; CYCLINE; ENDOTHELIN 1; ENDOTHELIN 2; FIBROBLAST GROWTH FACTOR 3; GELATINASE B; GLUTAMYL AMINOPEPTIDASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 8; KU ANTIGEN; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN BCL 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RIBOSEPHOSPHATE PYROPHOSPHOKINASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; TENASCIN; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNINDEXED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACIDITY; ANAEROBIC METABOLISM; ANGIOGENESIS; ANIMAL CELL; CANCER GROWTH; CELL INTERACTION; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETIC STABILITY; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; SOLID TUMOR;

ANIMALS; CELL HYPOXIA; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0037279517     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022939318102     Document Type: Review

References (134)

1. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997; 80: 1529-37.
2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
3. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
4. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-26.
5. Zhu Z, Sanchez-Sweatman O, Huang X et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001; 61: 1707-16.
6. Chambers AF, MacDonald IC, Schmidt EE et al. Steps in tumor metastasis: New concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995; 14: 279-301.
7. Al Mehdi AB, Tozawa K, Fisher AB et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis. Nat Med 2000; 6: 100-2.
8. Vaage J. A survey of in vivo growth characteristics and spontaneous metastasizing potentials of C3H mouse mammary tumors. Int J Cancer 1989; 43: 910-4.
9. Yoshida BA, Sokoloff MM, Welch DR et al. Metastasis-suppressor genes: A review and perspective on an emerging field. J Natl Cancer Inst 2000; 92: 1717-30.
10. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49.
11. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6: 10-21.
12. Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 1998; 8: 143-50.
13. Gazit Y, Berk DA, Leunig M et al. Scale-invariant behavior and vascular network formation in normal and tumor tissue. Phys Rev Lett 1995; 75: 2428-31.
14. Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 1995; 34: 571-87.
15. Hockel M, Schlenger K, Aral B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
16. Fyles A, Milosevic M, Hedley D et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002; 20: 680-7.
17. Rofstad EK, Sundfor K, Lyng H et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83: 354-9.
18. Rudat V, Vanselow B, Wollensack P et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol 2000; 57: 31-7.
19. Stadler P, Becker A, Feldmann HJ et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 44: 749-54.
20. Brizel DM, Dodge RK, Clough RW et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53: 113-7.
21. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-9.
22. Brizel DM, Scully SP, Harrelson JM et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3.
23. Nordsmark M, Alsner J, Keller J et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001; 84: 1070-5.
24. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
25. Kallinowski F, Schlenger KH, Runkel S et al. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 1989; 49: 3759-64.
26. Holm E, Hagmuller E, Staedt U et al. Substrate balances across colonic carcinomas in humans. Cancer Res 1995; 55: 1373-8.
27. Yamagata M, Hasuda K, Stamato T et al. The contribution of lactic acid to acidification of tumours: Studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998; 77: 1726-31.
28. Newell K, Franchi A, Pouyssegur J et al. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 1993; 90: 1127-31.
29. Griffiths JR, McIntyre DJ, Howe FA et al. Why are cancers acidic? A carrier-mediated diffusion model for H+ transport in the interstitial fluid. Novartis Found Symp 2001; 240: 46-62.
30. Walenta S, Wetterling M, Lehrke M et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000; 60: 916-21.
31. Walenta S, Salameh A, Lyng H et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 1997; 150: 409-15.
32. Schwickert G, Walenta S, Sundfor K et al. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 1995; 55: 4757-9.
33. Milosevic M, Fyles A, Hill R. Interstitial fluid pressure in cervical cancer: guide to targeted therapy. Am J Clin Oncol 2001; 24: 516-21.
34. Rofstad EK, Tunheim SH, Mathiesen B et al. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res 2002; 62: 661-4.
35. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 1988; 85: 9533-7.
36. Young SD, Hill RP. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst 1990; 82: 371-80.
37. De Jaeger K, Kavanagh MC, Hill RP. Relationship of hypoxia to metastatic ability in rodent turnouts. Br J Cancer 2001; 84: 1280-5.
38. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 2001; 61: 8903-8.
39. Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 1999; 80: 1697-707.
40. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56: 5754-7.
41. Hill RP. Tumor progression: Potential role of unstable genomic changes. Cancer Metastasis Rev 1990; 9: 137-47.
42. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-9.
43. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
44. Semenza GL. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7: 345-50.
45. Cockman ME, Masson N, Mole DR et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275: 25733-41.
46. Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
47. Masson N, Willam C, Maxwell PH et al. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20: 5197-206.
48. Lando D, Peer DJ, Whelan DA et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295: 858-61.
49. Laughner E, Taghavi P, Chiles K et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
50. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
51. Iyer NV, Kotch LE, Agani F et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-62.
52. Veikkola T, Karkkainen M, Claesson-Welsh L et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203-12.
53. Dvorak HF, Nagy JA, Feng D et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97-132.
54. Wang GL, Semenza GL. Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol 1996; 3: 156-62.
55. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-54.
56. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 1994; 54: 1425-30.
57. Graeber TG, Peterson JF, Tsai M et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-77.
58. Yao KS, Xanthoudakis S, Curran T et al. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol 1994; 14: 5997-6003.
59. Yan SF, Zou YS, Mendelsohn M et al. Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia. J Biol Chem 1997; 272: 4287-94.
60. Yan SF, Lu J, Zou YS et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999; 274: 15030-40.
61. Wu X, Bishopric NH, Discher DJ et al. Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol Cell Biol 1996; 16: 1035-46.
62. Discher DJ, Bishopric NH, Wu X et al. Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved, GC element. J Biol Chem 1998; 273: 26087-93.
63. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-801.
64. Moghaddam A, Zhang HT, Fan TP et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92: 998-1002.
65. Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol Int 1995; 19: 431-44.
66. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-8.
67. Luzzi KJ, MacDonald IC, Schmidt EE et al. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153: 865-73.
68. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000; 60: 4932-8.
69. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-64.
70. Tosetti F, Ferrari N, De Flora S et al. Angioprevention: Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14.
71. Solorzano CC, Baker CH, Brans CJ et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2001; 16: 359-70.
72. Kanayama H, Yano S, Kim SJ et al. Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clin Exp Metastasis 1999; 17: 831-40.
73. Jang A, Hill RP. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin Exp Metastasis 1997; 15: 469-83.
74. Schadendorf D, Moller A, Algermissen B et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151: 2667-75.
75. Norgauer J, Metzner B, Schraufstatter I. Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol 1996; 156: 1132-7.
76. Shi Q, Abbruzzese JL, Huang SY et al. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999; 5: 3711-21.
77. Inoue K, Slaton JW, Kim SJ et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000; 60: 2290-9.
78. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999; 67: 12-8.
79. Rofstad EK, Halsor EF. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: Involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 2002; 86: 301-8.
80. Griffiths L, Dachs GU, Bicknell R et al. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997; 57: 570-2.
81. Hartmann A, Kunz M, Kostlin S et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999; 59: 1578-83.
82. Shi QA, Le XD, Abbruzzese JL et al. Cooperation between transcription factor AP-1 and NF-kappa B in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res 1999; 19: 1363-71.
83. Kunz M, Hartmann A, Flory E et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol 1999; 155: 753-63.
84. Huang SY, DeGuzman A, Bucana CD et al. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappa B activity. Cytokines Cell Mol Ther 2000; 6: 9-17.
85. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2: 161-74.
86. Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 1998; 91: 3300-7.
87. Graham CH, Forsdike J, Fitzgerald CJ et al. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999; 80: 617-23.
88. Maity A, Solomon D. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Exp Cell Res 2000; 255: 250-7.
89. Fink T, Kazlauskas A, Poellinger L et al. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 2002; 99: 2077-83.
90. Lash GE, Fitzpatrick TE, Graham CH. Effect of hypoxia on cellular adhesion to vitronectin and fibronectin. Biochem Biophys Res Commun 2001; 287: 622-9.
91. Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-5.
92. Friedl P, Brocker EB. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci 2000; 57: 41-64.
93. Rofstad EK, Rasmussen H, Galappathi K et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by upregulating the urokinase-type plasminogen activator receptor. Cancer Res 2002; 62: 1847-53.
94. Canning MT, Postovit LM, Clarke SH et al. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 2001; 267: 88-94.
95. Birchmeier W, Behrens J. Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994; 1198: 11-26.
96. Hasan NM, Adams GE, Joiner MC et al. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer 1998; 77: 1799-805.
97. Gao AC, Lou W, Dong JT et al. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57: 846-9.
98. Mazure NM, Chauvet C, Bois-Joyeux B et al. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: Characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res 2002; 62: 1158-65.
99. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5.
100. Aebersold DM, Burri P, Beer KT et al. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-6.
101. Birner P, Schindl M, Obermair A et al. Overexpression of hypoxiainducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-6.
102. Turner KJ, Crew JP, Wykoff CC et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 2002; 86: 1276-82.
103. Charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 2001; 92: 556-68.
104. Agrawal D, Chen T, Irby R et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-21.
105. Rudland PS, Platt-Higgins A, El Tanani M et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417-27.
106. Grondahl-Hansen J, Christensen IJ, Briand P et al. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 1997; 3: 233-9.
107. Loncaster JA, Harris AL, Davidson SE et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 6394-9.
108. Koukourakis MI, Giatromanolaki A, Sivridis E et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7: 3399-403.
109. Airley R, Loncaster J, Davidson S et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001; 7: 928-34.
110. Koong AC, Denko NC, Hudson KM et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000; 60: 883-7.
111. Denko NC, Schindler C, Koong A et al. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 2000; 6: 480-7.
112. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994; 22: 5640-8.
113. Hubank M, Schatz DG. cDNA representational difference analysis: A sensitive and flexible method for identification of differentially expressed genes. Methods Enzymol 1999; 303: 325-49.
114. Lal A, Peters H, St Croix B et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001; 93: 1337-43.
115. Velculescu VE, Zhang L, Vogelstein B et al. Serial analysis of gene expression. Science 1995; 270: 484-7.
116. Beasley NJ, Wykoff CC, Watson PH et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 5262-7.
117. Olive PL, Aquino-Parsons C, MacPhail SH et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001; 61: 8924-9.
118. Scandurro AB, Weldon CW, Figueroa YG et al. Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int J Oncol 2001; 19: 129-35.
119. Attwell S, Roskelley C, Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 2000; 19: 3811-5.
120. White DE, Cardiff RD, Dedhar S et al. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 2001; 20: 7064-72.
121. Wykoff CC, Pugh CW, Maxwell PH et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000; 19: 6297-305.
122. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
123. Yoon DY, Buchler P, Saarikoski ST et al. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 2001; 288: 882-6.
124. Watanabe H, Takehana K, Date M et al. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996; 56: 2960-3.
125. Lagana A, Duchaine T, Raz A et al. Expression of autocrine motility factor/phosphohexose isomerase in Cos7 cells. Biochem Biophys Res Commun 2000; 273: 213-8.
126. Guirguis R, Margulies I, Taraboletti G et al. Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. Nature 1987; 329: 261-3.
127. Seiki M, Sato H, Liotta LA et al. Comparison of autocrine mechanisms promoting motility in two metastatic cell lines: Human melanoma and ras-transfected NIH3T3 cells. Int J Cancer 1991; 49: 717-20.
128. Nam SW, Clair T, Kim YS et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001; 61: 6938-44.
129. Shen M, Kawamoto T, Yan W et al. Molecular characterization of the novel basic helix-loop-helix protein DEC1 expressed in differentiated human embryo chondrocytes. Biochem Biophys Res Commun 1997; 236: 294-8.
130. Shen M, Kawamoto T, Teramoto M et al. Induction of basic helix-loop-helix protein DEC1 (BHLHB2)/Stra13/Sharp2 in response to the cyclic adenosine monophosphate pathway. Eur J Cell Biol 2001; 80: 329-34.
131. Knocke TH, Weitmann HD, Feldmann HJ et al. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999; 53: 99-104.
132. Sandhu JK, Birnboim HC. Mutagenicity and cytotoxicity of reactive oxygen and nitrogen species in the MN-11 tumor cell line. Mutat Res 1997; 379: 241-52.
133. Horsman MR, Nordsmark M, Overgaard J. Techniques to assess the oxygenation of human tumors. State of the art. Strahlenther Onkol 1998; 174: 2-5.
134. Sundfor K, Lyng H, Trope CG et al. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: Relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol 2000; 54: 101-7.